Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pneumonia
Conditions
Keywords
Nigella Sativa Oil, Pneumonia
Brief summary
Nigella sativa is the world's oldest immunomodulator. The main active component in Nigella sativa is thymoquinone. Research shows thymoquinone has antioxidant, anti-inflammatory, and antimicrobial effects. Based on these observations on the pharmacological activities of Nigella sativa, the potential therapeutic efficacy of N. Sativa was proposed in CAP.
Detailed description
The aim of this work is to assess the benefit of oral Nigella Sativa oil supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with pneumonia admitted to the Pulmonology Unit, Pediatric Department. Primary outcome: 1- The duration of clinical manifestations of pneumonia including time taken for normalization of respiratory rate, temperature, and oxygen. saturation, chest in drawing, hypoxia, lethargy, and inability to feed 2- The duration of hospital stay. Secondary outcome: 1. Discharge or death of the patient. 2. Occurrence of pneumonia complications.
Interventions
Nigella Sativa Oil as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia
Sponsors
Rehab Zaki Elmeazawy
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
2 Months to 18 Years
Healthy volunteers
No
Inclusion criteria
* Signs and symptoms of lower respiratory tract infections (LRTI) (LRTI was defined as ≥ 1 of the following: new or different cough or sputum production, chest pain, dyspnea, tachypnea, or abnormal auscultatory findings). * Focal findings on chest x-ray indicating pneumonia.
Exclusion criteria
* Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders….etc, children with CHD affecting the pulmonary blood flow
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hospital stays | 14 days | Duration of hospital stay |
| Feeding | 3 days | Duration of improvement of feeding |
| Respiratory distress | 7 days | Duration of improvement of respiratory distress |
| Respiratory rate | 3 days | Time taken for normalization of respiratory rate |
| Temperature | 3 days | Duration of defeverness |
| Oxygen saturation | 3 days | Duration of normal oxygen saturation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pneumonia complications | 30 days | Occurrence of pneumonia complications |
| Mortality | 30 days | Discharge or death of the patient |
Countries
Egypt
Contacts
Primary ContactRehab Zaki Elmeazawy, MD
Backup ContactAhmed A. Aboelezz, MD
Outcome results
None listed